Loading clinical trials...

Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL | Clinical Trials | Clareo Health

COMPLETEDPhase 2NCT00369707

Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL

Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block canc...

Lead sponsor: Northwestern University•4 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Related studies

RECRUITING

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

NCT00131014 · Non-Hodgkin's Lymphoma, Hodgkin's Disease, and more

RECRUITINGPhase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

NCT05735717 · Hematologic Malignancy, Acute Leukemia, and more

RECRUITINGPhase 1

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

NCT06667687 · Non-Hodgkin's Lymphoma

RECRUITINGPhase 1

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

NCT04664179 · EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, and more

RECRUITINGPhase 1

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

NCT07239323 · B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 6, 2019Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment42

Start dateAug 2006

Last updatedSep 6, 2019

Condition

Non-Hodgkin's Lymphoma

Locations shown

University of Miami Sylvester Comprehensive Cancer Center - Miami

Miami, Florida

Hematology-Oncology Associates of Illinois

Chicago, Illinois

Northwestern University

Chicago, Illinois

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 6, 2019Data synced to Clareo: May 16, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

Trial snapshot

Condition

Locations shown

For caregivers